WELCOME TO
BSG LIVE’25

Atrophic gastritis (AG) represents a significant clinical challenge due to its non-specific symptoms and role as a precursor to gastric cancer. Diagnosis via gastroscopy is invasive, costly and resource intensive, and experts agree that there is a need for an effective triage tool to select or exclude dyspeptic patients before gastroscopy referral. Serologic pre-screening for AG-specific biomarkers – notably pepsinogen I (PGI) and the PGI/PGII ratio – provides an effective method for stratifying patients based on risk. In this talk, Dr Cinzia Papadia will discuss her recent research evaluating the efficacy of serologic biomarker testing for identifying moderate to severe corpus AG among dyspeptic patients, and stratifying those who would most benefit from gastroscopic examinations.

This study is the first of its kind in the UK to highlight the clinical validity of biomarker testing, showing an overall 90 % agreement between serologic testing and current gold standard histology. By exploring comparisons with current diagnostic practices, attendees will understand the clinical and economic implications of integrating serological screening into existing care pathways, ultimately streamlining patient management, reducing unnecessary endoscopies and improving resource allocation.